

18 June 2018

NSX Announcement

INVESTMENT INTO YOUTOKUKAI

Beroni Group (ASX: BTG) (“Beroni Group”) is pleased to announce that it has signed an investment agreement with the Japanese Medical Corporation Youtokukai (“Youtokukai”) to invest JPY100 million into a capital fund; Youtokukai Foundation which was set up to fund the establishment and development of the Tokyo Ginza International Medical Clinic (Medical Clinic) to be operated by Youtokukai. A consortium of four investors including Beroni Group will be investing a total of JPY280 million in this capital fund. The fund will be used to set up the Medical Clinic and related facilities and will include a stem cell processing centre for treatment of cancer patients. The Medical Clinic is going to be wholly owned by Youtokukai.

Investment Terms

The JPY100 million investment by Beroni Group can be fully redeemed after 30 June 2021. For its investment, Beroni Group will receive a monthly dividend from January 2019 onwards based on the operating surplus of the business and its share of the total investment in this joint venture. In addition, Beroni Japan Inc. (“Beroni Japan”), a new Japanese company set up on 23 April 2018 and 51% owned by Beroni Group, will act as a manager for this investment fund and will receive a monthly management fee based on 10% of the operating surplus before paying the dividends to the four investors. Dendrix Inc. (“Dendrix”), whom Beroni Group has recently invested into, will provide stem cell processing technology and support to the clinics managed by Youtokukai.

Beroni’s Executive Chairman, Mr Jacky Zhang said: “This investment further strengthens our competitive position in Japan in the field of stem cell technology and advances our international presence as a leading stem cell technology company. Our partnership with Dendrix and Youtokukai will bring together the best medical expertise in Japan and China to explore effective immune cell therapies for treatment of cancer. Going forward, Beroni Group, Dendrix and Youtokukai will work closely together to share new technologies, innovation and patents for mutual development especially in regenerative medicine.”

About Youtokukai

Youtokukai is headed by Dr. Morihito Sato with the support of Dr. Masato Maeda and Dr. Kuwayama Hajime. Youtokukai provides Hybrid Cancer Care Treatment, a technique using molecular science technology, immune cell therapy, gene therapy, thermal treatment by microwave and intensity modulated radiation therapy to provide a comprehensive treatment for cancer patients. Youtokukai has two medical institutions, the Dojima Life Care Clinic based in Osaka and the Ginza TENGENJI Clinic based in Tokyo. The new Medical Clinic will be opened in September 2018. Its purpose is to provide patients with the latest medical treatment using



regenerative medicine technology such as gene therapy, immune cell therapy, and stem cell therapy.

For further information please contact:

Mr Jacky Zhang

Executive Chairman

Tel: +86 1851 6931 911

E: 1710426553@qq.com

Mr Peter Wong

Non-Executive Director

Tel: +61 423 727 580

E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX:BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group's overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.

Beroni Group Limited ACN 613 077 526

A: Level 36, Gateway Tower, 1 Macquarie Place, Sydney NSW 2000

Tel: +61 478 042 056

Email: beronigroup_au@126.com